#United States #San Francisco #Genetic Testing #Allelica #AbsoluteDx

Allelica Unveils AbsoluteDx

Allelica, a leading company in clinical polygenic risk score (PRS) testing, has officially launched AbsoluteDx, a revolutionary genetic testing tool that combines both monogenic and polygenic risk assessments into a single, cohesive solution. This launch positions Allelica at the forefront of precision medicine, aiming to enhance the understanding of inherited disease risk and drive proactive, tailored healthcare for patients.

## A Game Changer in Genetic Testing
In the healthcare landscape, the inadequacies in patient risk assessments often stem from the inability to consider both monogenic and polygenic factors simultaneously. For instance, two individuals might share the same monogenic mutation, such as those associated with breast cancer in the CHEK2 gene, yet their overall risk can differ significantly owing to variations in their breast cancer PRS. This crucial nuance indicates that personalized treatment is essential. AbsoluteDx effectively bridges this gap by capturing the interaction between monogenic mutations and polygenic risk—an area frequently overlooked by existing practices. Consequently, healthcare providers gain the confidence to offer accurate, personalized care backed by the most comprehensive genetic data available.

## Efficiency Meets Accuracy
One of the standout features of AbsoluteDx is its efficiency. Instead of ordering separate tests for monogenic and polygenic assessments, healthcare providers can utilize AbsoluteDx as a cost-effective and comprehensive option for precision prevention. The test requires just a single, non-invasive saliva sample, enabling patients to access an extensive array of genetic insights with relative ease.

The panel covers a wide spectrum of genetic testing, including monogenic evaluations across various genes associated with severe health conditions. These conditions encompass hereditary cancer syndromes, cardiovascular risks, as well as metabolic and neurological disorders. Additionally, the test offers multi-ancestry PRS for these same diseases, significantly improving the likelihood of detecting risks that traditional testing methods often miss.

## Targeted Solutions for Specific Diseases
Expanding upon the AbsoluteDx offering, Allelica has also rolled out disease-specific panels, including AbsoluteDx Breast Cancer, AbsoluteDx Prostate Cancer, and AbsoluteDx Cardio. These specialized panels provide healthcare professionals with targeted tools tailored to manage and identify patients at risk for particular diseases, ensuring that interventions can be made more effectively.

## Commitment to Scientific Rigor
Allelica's partnership with the Broad Institute, a leader in innovation and precision medicine, underscores the clinical reliability of AbsoluteDx, presenting it as a scientifically robust tool built within a nationally certified laboratory. This collaboration guarantees that the testing meets the highest standards of clinical and scientific efficacy, a vital requirement in the field of genetics.

Dr. Giordano Bottà, CEO of Allelica, expressed that the launch of AbsoluteDx is a significant milestone for the company, marking a new era in clinical genomics. His vision for integrating monogenic and polygenic insights aims to make preventive medicine more precise, actionable, and personalized than ever before. This novel approach will empower healthcare providers with a powerful tool that can potentially lower the risks of common diseases such as coronary artery disease and breast cancer.

## Transforming Preventive Care
With the introduction of AbsoluteDx, Allelica reinforces its commitment to delivering personalized genetic risk assessment tools, fostering advancements in preventive care while lessening the impact of prevalent diseases. The seamless blend of comprehensive testing heightens the potential for healthcare providers to implement highly individualized patient care strategies based on genetic predispositions.

For healthcare providers interested in offering AbsoluteDx to their patients, Allelica encourages them to reach out via email at [email protected] or by phone at 202-949-2834.

### About Allelica
Allelica is a pioneering precision medicine company specializing in multi-ancestry PRS, which predicts genetic risks for common diseases across diverse populations. Through the integration of advanced bioinformatics and multi-ancestry assessments, Allelica aims to empower healthcare systems and physicians to mitigate the burden of common diseases. Supported by significant research publications and an extensive intellectual property portfolio, Allelica is dedicated to transforming how genetics inform preventive healthcare strategies. To learn more about their groundbreaking solutions, visit allelica.com.